bevacizumab [Bevacizumab]

tematický
445
Termíny

Avastin

 

Avastin
Bevacizumab-awwb
Mvasi

Perzistentní odkaz   https://www.medvik.cz/link/D000068258
Definice

Bevacizumab (Avastin) je humanizovaná monoklonální protilátka proti ligandu VEGF (vaskulárnímu endoteliálnímu růstovému faktoru). Bevacizumab váže volný VEGF-A, -B i -C a účinně blokuje novotvorbu cév u mnoha typů nádorů inhibicí signální dráhy VEGF-VEGFR.

An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.

DUI
D000068258 MeSH Prohlížeč
CUI
M0443627
Historická pozn.
2016 (2002)
Veřejná pozn.
2016; BEVACIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2015, and under ANTIBODIES, MONOCLONAL 2002-2011

Povolená podhesla

AN
analýza 1
AD
aplikace a dávkování 124
BI
biosyntéza
CH
chemie
HI
dějiny
EC
ekonomika 5
PK
farmakokinetika 17
PD
farmakologie 58
PH
fyziologie
GE
genetika
IM
imunologie
IP
izolace a purifikace
CL
klasifikace
BL
krev
ME
metabolismus
UR
moč
CF
mozkomíšní mok
PO
otrava
AE
škodlivé účinky 69
TU
terapeutické užití 226
TO
toxicita 1
DE
účinky léků 3
RE
účinky záření
UL
ultrastruktura

D Chemikálie a léčiva
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 577
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 489
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.224 monoklonální protilátky 4 629
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 347
D12.776.124.486.485.114.224.060.313 alemtuzumab 123
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 445
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 40
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 185
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 150
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 253
D12.776.124.486.485.114.224.060.813 natalizumab 156
D12.776.124.486.485.114.224.060.829 nivolumab 432
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 57
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 269
D12.776.124.486.485.114.224.060.937 ustekinumab 121
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 489
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.224 monoklonální protilátky 4 629
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 347
D12.776.124.790.651.114.224.060.375 alemtuzumab 123
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 445
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 40
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 185
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 150
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 253
D12.776.124.790.651.114.224.060.813 natalizumab 156
D12.776.124.790.651.114.224.060.829 nivolumab 432
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 57
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 269
D12.776.124.790.651.114.224.060.937 ustekinumab 121
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 489
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.224 monoklonální protilátky 4 629
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 790
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 347
D12.776.377.715.548.114.224.200.375 alemtuzumab 123
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 445
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 40
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 185
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 150
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 253
D12.776.377.715.548.114.224.200.813 natalizumab 156
D12.776.377.715.548.114.224.200.829 nivolumab 432
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 57
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 269
D12.776.377.715.548.114.224.200.937 ustekinumab 121

89Zr-bevacizumab Chemical MeSH Prohlížeč

BEVZ92 Chemical MeSH Prohlížeč

technetium 99m tricarbonyl bevacizumab Chemical MeSH Prohlížeč

Přidat